See more : Dateline Resources Limited (DTR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Genprex, Inc. (GNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genprex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bonheur ASA (BNHUF) Income Statement Analysis – Financial Results
- Carisma Therapeutics, Inc. (CARM) Income Statement Analysis – Financial Results
- Red Star Macalline Group Corporation Ltd. (1528.HK) Income Statement Analysis – Financial Results
- Ad-Sol Nissin Corporation (3837.T) Income Statement Analysis – Financial Results
- American Lithium Corp. (LI.V) Income Statement Analysis – Financial Results
Genprex, Inc. (GNPX)
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 23.83M | 22.53K | 22.78K | 13.07K | 5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -23.83M | -22.53K | -22.78K | -13.07K | -5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.62M | 11.51M | 8.61M | 7.30M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| General & Administrative | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Other Expenses | 0.00 | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 0.00 | 0.00 |
| Operating Expenses | 31.06M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Cost & Expenses | 31.08M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Interest Income | 215.11K | 90.10K | 5.13K | 18.81K | 27.91K | 29.18K | 80.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.98K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00K | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 862.00 | 2.06K |
| EBITDA | -31.06M | -23.81M | -20.65M | -17.94M | -10.64M | -12.33M | -3.31M | -4.13M | -1.07M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.08M | -23.83M | -19.60M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.11K | 90.10K | 5.13K | 18.81K | 27.90K | -8.80K | -1.81K | 0.00 | 0.00 |
| Income Before Tax | -30.86M | -23.74M | -19.60M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.72M | -5.13K | -18.81K | -130.89K | 29.18K | 80.00 | 0.00 | 0.00 |
| Net Income | -30.86M | -29.46M | -19.59M | -17.92M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.58 | -24.59 | -16.64 | -20.18 | -26.64 | -35.97 | -11.55 | -15.30 | -23.25 |
| EPS Diluted | -22.56 | -24.58 | -16.64 | -20.18 | -26.59 | -35.94 | -11.53 | -15.26 | -22.93 |
| Weighted Avg Shares Out | 1.37M | 1.20M | 1.18M | 888.00K | 400.00K | 344.00K | 287.00K | 270.00K | 46.00K |
| Weighted Avg Shares Out (Dil) | 1.37M | 1.20M | 1.18M | 888.07K | 400.68K | 344.28K | 287.50K | 270.87K | 46.66K |
Genprex to Participate in September Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating...
Genprex gears up for patient enrollment in its Acclaim-1 REQORSA trial after FDA feedback
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) is gearing up to enroll patients in its Acclaim-1 clinical trial evaluating its lead drug candidate REQORSA in combination with AstraZeneca PLC's (LON:AZN) (NASDAQ:AZN) Tagrisso (osimertinib) for late-stage non-small cell lung cancer following a review from...
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer
Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and related technology for lung cancer treatment. The newly licensed...
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancer
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (NSCLC). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines...
Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA
Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC)....
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting
Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). These data were presented...
Wall Street starts in the red
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therapeutics Inc (NASDAQ:KTRA) says interim Phase 2 study data on VAL-083 shows its potential as...
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting
Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two presentations at the six-day virtual annual meeting of the American...
Genprex announces $25 million registered direct offering priced at-the-market
Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct...
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Source: https://incomestatements.info
Category: Stock Reports